View Future GrowthEli Lilly 過去の業績過去 基準チェック /56Eli Lillyは、平均年間31.1%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.1% 20.8%収益成長率で 成長しています。 Eli Lillyの自己資本利益率は95.3%であり、純利益率は35%です。主要情報31.07%収益成長率31.32%EPS成長率Pharmaceuticals 業界の成長12.39%収益成長率20.77%株主資本利益率95.26%ネット・マージン34.99%次回の業績アップデート05 Aug 2026最近の業績更新First quarter 2026 earnings released: EPS: US$8.26 (vs US$3.07 in 1Q 2025) May 01Full year 2025 earnings released: EPS: US$22.95 (vs US$11.76 in FY 2024) Feb 05Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026Jan 21Third quarter 2025 earnings released: EPS: US$6.21 (vs US$1.08 in 3Q 2024) Oct 31Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025Oct 16Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025Jul 24すべての更新を表示Recent updatesEli Lilly and Company Raises Earning Guidance for the Year 2026May 03First quarter 2026 earnings released: EPS: US$8.26 (vs US$3.07 in 1Q 2025) May 01Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.Apr 27Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 BillionApr 21+ 1 more updateEli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular RiskApr 17+ 1 more updateEli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire CrossBridge Bio, Inc. from Portal Innovations, LLC, The Texas Medical Center Venture Fund, Alexandria Venture Investments, LLC, Linden Lake Venture Capital, Cancer Prevention and Research Institute of Texas and Crescent Enterprises Venture Capital for $300 million.Apr 16Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLLApr 14Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.SApr 09Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight LossApr 01Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.Mar 31Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and ObesityMar 30Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic DermatitisMar 27Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 DiabetesMar 19Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic DermatitisMar 16Eli Lilly and Company, Annual General Meeting, May 04, 2026Mar 09Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding ActosMar 07Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage OptionsMar 05+ 1 more updateEli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia AreataFeb 27Eli Lilly and Company Announces Detailed Results from ACHIEVE-3Feb 26Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)Feb 23Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)Feb 20Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)Feb 18Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of RetevmoFeb 16Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.Feb 09Upcoming dividend of US$1.73 per share Feb 06Full year 2025 earnings released: EPS: US$22.95 (vs US$11.76 in FY 2024) Feb 05Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026Feb 04New minor risk - Share price stability Jan 29Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026Jan 21Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian CancerJan 20Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo NordiskJan 15Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)Jan 09Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.Jan 08Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli LillyJan 07Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).Jan 02Eli Lilly and Company Announces Oral GLP-1 OrforglipronDec 20Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trialDec 18Third quarter dividend of US$1.73 announced Dec 15Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast CancerDec 13Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical TrialDec 11Insufficient new directors Dec 10Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)Dec 09+ 2 more updatesEli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)Dec 04Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli LillyNov 26Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual MeetingNov 25+ 1 more updateEli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025Nov 22Eli Lilly and Company Announces Management AppointmentsNov 07Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of EloralintideNov 06Third quarter dividend of US$1.50 announced Nov 03Third quarter 2025 earnings released: EPS: US$6.21 (vs US$1.08 in 3Q 2024) Oct 31Eli Lilly and Company Raises Earnings Guidance for the Year 2025Oct 30Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative ColitisOct 28+ 1 more updateEli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative ColitisOct 27Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.Oct 24+ 1 more updateEli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche TrialOct 17Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025Oct 16Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 TrialsOct 15Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule DiscoveryOct 09Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four YearsOct 07Investor sentiment improves as stock rises 16% Oct 03Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast CancerSep 26+ 1 more updateNow 21% undervalued after recent price drop Sep 25Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of MounjaroSep 18Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3Sep 17+ 1 more updateEli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research InvestmentSep 09Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of JaypircaSep 08Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung CancerSep 04Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE TrialAug 27Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 TrialAug 26Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025Aug 20Ken Paxton Files Lawsuit in State Court Against Eli Lilly and CoAug 15Chairman recently bought Mex$20m worth of stock Aug 14Independent Director recently bought Mex$2.4m worth of stock Aug 09Upcoming dividend of US$1.50 per share Aug 08Eli Lilly and Company Raises Earning Guidance for the Year 2025Aug 07+ 1 more updateEli Lilly and Company Announces Topline Results from SURPASS-CVOTJul 31Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 StudyJul 30Now 22% undervalued after recent price drop Jul 29Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of JaypircaJul 29Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's DiseaseJul 25Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025Jul 24Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's DiseaseJul 09Now 20% undervalued after recent price drop Jul 08First quarter dividend of US$1.50 announced Jul 01Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025Jun 24Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora AlfaJun 23Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise AloneJun 22Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli LillyJun 19収支内訳Eli Lilly の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BMV:LLY * 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 2672,24925,27711,56014,11331 Dec 2565,17920,64011,09413,33730 Sep 2559,42018,4129,94512,55830 Jun 2553,25813,8009,30311,82631 Mar 2549,00311,1068,65811,20231 Dec 2445,04310,5908,59410,99130 Sep 2440,8638,3707,63310,53130 Jun 2438,9237,3427,33710,20631 Mar 2435,9326,1387,1449,85131 Dec 2334,1245,2407,4049,31330 Sep 2332,0734,9886,6828,74730 Jun 2329,5166,4986,5158,14031 Mar 2327,6915,6876,2367,56631 Dec 2228,5416,2456,0687,19130 Sep 2229,2406,0336,0377,09330 Jun 2229,0715,6926,0206,99631 Mar 2229,3236,1296,1046,86931 Dec 2128,3185,5826,1426,93130 Sep 2127,7595,9726,1196,87030 Jun 2126,7266,0716,0696,63131 Mar 2125,4866,0935,8676,36631 Dec 2024,5406,1945,8695,97630 Sep 2023,2145,5736,0195,82930 Jun 2022,9505,6185,9245,74531 Mar 2023,0875,5336,0485,75731 Dec 1922,3204,6386,0045,59530 Sep 1921,8434,2645,9845,40530 Jun 1921,6734,1036,0195,30531 Mar 1921,6222,5455,9135,17431 Dec 1821,4933,1515,7355,05130 Sep 1822,0163725,8555,14630 Jun 1822,368-1665,9755,20531 Mar 1822,6071,0746,2105,20731 Dec 1719,974-865,7335,09630 Sep 1722,4712,2256,4755,32130 Jun 1722,0052,4476,5265,21731 Mar 1721,5852,1876,4835,28131 Dec 1621,2222,7386,3305,31030 Sep 1620,8372,4446,4605,23830 Jun 1620,6052,4666,4715,14531 Mar 1620,1792,3196,4834,97831 Dec 1519,9592,4086,5334,79630 Sep 1519,7042,3596,5354,53830 Jun 1519,6202,0596,6314,638質の高い収益: LLY *は 高品質の収益 を持っています。利益率の向上: LLY *の現在の純利益率 (35%)は、昨年(22.7%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: LLY *の収益は過去 5 年間で年間31.1%増加しました。成長の加速: LLY *の過去 1 年間の収益成長率 ( 127.6% ) は、5 年間の平均 ( 年間31.1%を上回っています。収益対業界: LLY *の過去 1 年間の収益成長率 ( 127.6% ) はPharmaceuticals業界7%を上回りました。株主資本利益率高いROE: LLY *の 自己資本利益率 ( 95.26% ) は 抜群 ですが、負債レベルが高いためこの指標は歪んでいます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 05:29終値2026/04/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Eli Lilly and Company 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53 アナリスト機関David ToungArgus Research CompanyEmily FieldBarclaysKerry HolfordBerenberg50 その他のアナリストを表示
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.Apr 27
Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 BillionApr 21+ 1 more update
Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular RiskApr 17+ 1 more update
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire CrossBridge Bio, Inc. from Portal Innovations, LLC, The Texas Medical Center Venture Fund, Alexandria Venture Investments, LLC, Linden Lake Venture Capital, Cancer Prevention and Research Institute of Texas and Crescent Enterprises Venture Capital for $300 million.Apr 16
Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLLApr 14
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.SApr 09
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.Mar 31
Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and ObesityMar 30
Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic DermatitisMar 27
Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 DiabetesMar 19
Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic DermatitisMar 16
Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding ActosMar 07
Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage OptionsMar 05+ 1 more update
Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia AreataFeb 27
Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)Feb 23
Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)Feb 20
Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)Feb 18
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of RetevmoFeb 16
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.Feb 09
Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian CancerJan 20
Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo NordiskJan 15
Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)Jan 09
Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.Jan 08
Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).Jan 02
Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast CancerDec 13
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical TrialDec 11
Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)Dec 09+ 2 more updates
Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)Dec 04
Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual MeetingNov 25+ 1 more update
Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025Nov 22
Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of EloralintideNov 06
Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative ColitisOct 28+ 1 more update
Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative ColitisOct 27
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.Oct 24+ 1 more update
Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche TrialOct 17
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 TrialsOct 15
Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule DiscoveryOct 09
Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four YearsOct 07
Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast CancerSep 26+ 1 more update
Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of MounjaroSep 18
Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research InvestmentSep 09
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of JaypircaSep 08
Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung CancerSep 04
Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE TrialAug 27
Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025Aug 20
Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 StudyJul 30
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of JaypircaJul 29
Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's DiseaseJul 25
Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's DiseaseJul 09
Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025Jun 24
Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora AlfaJun 23
Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise AloneJun 22